DRKS00010146已完成不适用
Project CP2: Recruiting, Assessment, and Biobanking in the clinical research unit 256 with the title Mechanisms of Disturbed Emotion Processing in Borderline-Personality Disorder - KFO256 - CP2
Zentralinstitut für Seelische Gesundheit, Universität Heidelberg0 个研究点目标入组 1,264 人开始时间: 2016年3月16日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 1,264
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 15 Years 至 45 Years（—）
- 性别
- All
入选标准
- •Current Borderline Personality disorder:
- •min. 5 criteria IPDE (International Personality Disorder Examination);
- •Remitted Borderline Personality disorder:
- •max. 3 criteria IPDE about the last 2 years and min. 5 criteria at an earlier time point, as diagnosed by IPDE;
- •Posttraumaticstress Disorder (PTSD):
- •PTSD according to DSM-IV (SCID I); sexual abuse during childhood according to Childhood Trauma Questionnaire (CTQ);
- •Fibromyalgia: Criteria of the American College of Rheumatology (Wolfe et al., 2010);
- •Healthy Controlls:
- •No psychiatric Axis I disorder according life span; no BPD (SCID I and IPSE);
排除标准
- •- psychotropic medication
- •- lifetime diagnosis schizophrenia or bipoloar I disorder
- •- substance dependence within two years prior to study, current substance abuse (veryfied by negative urine drug screening)
- •- pregnancy
- •- history of epilepsy, brain trauma, brain tumor, or other significant neurological or medical condition
- •For imaging studies, additionally:
- •- metal implants or electric implants that cannot be removed
- •- claustrophobia
研究者
相似试验
进行中（未招募）
1 期
A Phase 2 placebo-controlled study to evaluate the mechanistic effect, safety, and tolerability of alvelestat (MPH966) in participants with alpha-1 (PiZZ or null genotype/phenotype) antitrypsin deficiencyEUCTR2018-001309-95-ESMereo BioPharma 4 Ltd182
进行中（未招募）
1 期
A Phase 2 placebo-controlled study to evaluate the mechanistic effect, safety, and tolerability of alvelestat (MPH966) in participants with alpha-1 antitrypsin deficiencyMedDRA version: 20.1Level: PTClassification code 10001806Term: Alpha-1 anti-trypsin deficiencySystem Organ Class: 10010331 - Congenital, familial and genetic disordersAlpha-1 antitrypsin deficiencyEUCTR2018-001309-95-SEMereo BioPharma 4 Ltd182
进行中（未招募）
1 期
A Phase 2 placebo-controlled study to evaluate the mechanistic effect, safety, and tolerability of alvelestat (MPH966) in participants with alpha-1 antitrypsin deficiencyAlpha-1 antitrypsin deficiencyEUCTR2018-001309-95-GBMereo BioPharma 4 Ltd182
进行中（未招募）
1 期
A Phase 2 placebo-controlled study to evaluate the mechanistic effect, safety, and tolerability of alvelestat (MPH966) in participants with alpha-1 (PiZZ or null genotype/phenotype) antitrypsin deficiencyAlpha-1 antitrypsin deficiencyEUCTR2018-001309-95-PLMereo BioPharma 4 Ltd182
进行中（未招募）
1 期
A Phase 2 placebo-controlled study to evaluate the mechanistic effect, safety, and tolerability of alvelestat (MPH966) in participants with alpha-1 antitrypsin deficiencyMedDRA version: 23.1Level: LLTClassification code 10001806Term: Alpha-1 anti-trypsin deficiencySystem Organ Class: 100000004850Alpha-1 antitrypsin deficiencyEUCTR2018-001309-95-BEMereo BioPharma 4 Ltd182